TY  - JOUR
A1  - Müller, Volkmar
A1  - Hörner, Manuel
A1  - Thill, Marc
A1  - Banys-Paluchowski, Maggie
A1  - Schmatloch, Sabine
A1  - Fasching, Peter A.
A1  - Harbeck, Nadia
A1  - Langanke, Dagmar
A1  - Uhrig, Sabrina
A1  - Häberle, Lothar
A1  - Fischer, Dorothea
A1  - Hein, Alexander
A1  - Fehm, Tanja N.
A1  - Goossens, Chloë
A1  - Terhaag, Jürgen
A1  - Heilenkötter, Uwe
A1  - Dall, Peter
A1  - Rudlowski, Christian
A1  - Wuerstlein, Rachel
A1  - Aydogdu, Mustafa
A1  - Keyver-Paik, Mignon-Denise
A1  - Hammerle, Carolin
A1  - Deuerling, Natalija
A1  - Stickeler, Elmar
A1  - Aktas, Bahriye
A1  - Belleville, Erik
A1  - Thoma, Martin
A1  - Ditsch, Nina
A1  - Baila, Yasmin
A1  - Roos, Christian
A1  - Mann, Christian
A1  - Iuliano, Caterina
A1  - Brucker, Sara Y.
A1  - Schneeweiss, Andreas
A1  - Hartkopf, Andreas D.
T1  - Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk
T2  - The Breast
N2  - Background
The optimal adjuvant endocrine treatment in premenopausal patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) early breast cancer (eBC) remains debated, particularly the choice between aromatase inhibitors plus ovarian function suppression (AI + OFS) or tamoxifen (TAM) with or without additional OFS. This study assessed the use of adjuvant endocrine therapies for premenopausal patients with intermediate/high-risk HRpos/HER2neg eBC.
Methods
CLEAR-B (AGO-B-059; NCT05870813) was a retrospective study analyzing data, collected from January 2016 to June 2019 and from January 2022 to December 2023 during the certification process of breast centers in Germany. Premenopausal patients with HRpos/HER2neg intermediate/high-risk eBC were eligible. Patient and disease characteristics, in addition to recommended and received adjuvant treatments, were evaluated.
Results
The number of registered patients was 3137, of whom 2789 had complete information on endocrine treatments (1717 for 2016–2019 and 1072 for 2022–2023). In 2016–2019, 8.4 % of the patients were recommended to be treated with AI + OFS, whereas in 2022–2023, the proportion of patients with a treatment recommendation for AI + OFS rose to 42.1 %. In 2016–2019, TAM monotherapy was most frequently recommended (80.8 %). Conversely, TAM + OFS was not commonly recommended (9.3 % in 2016–2019 and 16.5 % in 2022–2023). While no clear association between tumor stage and chosen endocrine therapy was found in 2016–2019, most patients with ≥stage IIA were recommended to be treated with AI + OFS in 2022–2023.
Conclusion
This analysis shows that treatment recommendation for AI + OFS in premenopausal patients with HRpos/HER2neg eBC increased relevantly in the past years, reflecting latest guideline recommendations.
Y1  - 2025
UR  - https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/121389
UR  - https://nbn-resolving.org/urn:nbn:de:bvb:384-opus4-1213894
SN  - 0960-9776
VL  - 81
SP  - 104458
PB  - Elsevier BV
ER  -